Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

NEWS Bausch & Lomb Sues Competition Over Copycat Formulation and 'Confusingly Similar' Product Name This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases ...

Shares of Bausch + Lomb ( BLCO 14.47%) rallied 15.7% as of 3:07 p.m. ET today. The stock is surging today on news the company is considering selling itself. Of note, Bausch + Lomb is the eye-care ...

Analyst Glen Santangelo of Jefferies reiterated a Buy rating on Bausch Health Companies (BHC – Research Report), reducing the price ...

This week, the Federal Reserve's decision to reduce interest rates by 50 basis points boosted share prices across the ...

In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Buy rating on Bausch + Lomb Corporation (BLCO – Research ...

Bausch + Lomb BLCO shares ended the last trading session 14.5% higher at $17.80. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Bausch & Lomb (NYSE:BLCO) may be worth around $28 a share in a potential takeover after reports that the eye care company is ...

Laval, Canada-based Bausch Health announced plans in 2020 to separate Bausch + Lomb into an independent, publicly traded company. The intent was to separate the eye care business, which includes ...